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Background: The aim of this study is to elucidate the optimal can-
didate of selective lymph node dissection (LND) that reduces the 
extent of mediastinal LND according to clinical information includ-
ing radiological evaluation in primary non–small-cell lung cancer 
(NSCLC) patients.
Methods: Eight hundred and seventy-six patients with 
clinical(c)-stage I NSCLC (adenocarcinoma and squamous cell 
carcinoma), who underwent complete surgical resection between 
January 2003 and December 2009 were included in this study. 
We elucidated the lymph node metastatic incidence and distribu-
tion according to the primary tumor lobe location and extracted 
the associated clinicopathological factors, especially thin-section 
computed tomographic findings, with mediastinal lymph node 
involvement.
Results: The total incidence of mediastinal lymph node metastasis 
was 9.1%. There were no cases with hilar and mediastinal lymph 
node metastasis in ground glass opacity-predominant tumors. There 
was no significant association of clinical factors with subcarinal 
lymph node metastasis in right upper-lobe and left upper-division 
adenocarcinoma. An elevated preoperative serum carcinoembryonic 
antigen level (p < 0.001) showed significant associations with upper 
mediastinal lymph node metastasis in the patients with bilateral 
lower-lobe primary lung adenocarcinoma.
Conclusions: It would be acceptable to perform selective LND 
in patients with c-stage I NSCLC with ground glass opacity- 
predominant tumor. Elevated serum carcinoembryonic antigen 
was associated with upper mediastinal lymph node involvement 
in lower-lobe primary lung adenocarcinoma with radiologically 
solid-predominant tumor. We should be careful when applying 
selective LND to patients with solid-predominant tumor, espe-
cially located in the lower lobe.
Key Words: Non–small-cell lung cancer, Mediastinal lymph node 
metastasis, Consolidation-to-tumor ratio, Solid-predominant, Selective 
lymph node dissection.
(J Thorac Oncol. 2015;10: 930–936)
Ever since Cahan1 first introduced lymph node dissection (LND) of the pulmonary hilum and mediastinum com-
bined with lobectomy (radical lobectomy) as an alternative 
to pneumonectomy in 1960 and Ramsey et al.2 subsequently 
demonstrated the prognostic impact of hilar and mediasti-
nal LND in 1969, systematic LND has been accepted as a 
standard mode of surgery for resectable non–small-cell lung 
cancer (NSCLC) for over 50 years all around the world. This 
procedure has been believed to contribute to survival and/or to 
the determination of more accurate cancer staging.
Recently, two controversies have arisen about the con-
cept of LND, which consist of how to perform lymph node 
harvesting and how to decide the extent of LND. As regards 
the first issue, some randomized controlled trials that com-
pared systematic LND with systematic lymph node sampling 
have been performed, and the clinical implications of system-
atic LND have been discussed in these studies.3–6 In a recent 
pivotal study, ACOSOG Z0030, Darling et al. demonstrated 
that mediastinal LND does not improve survival in patients 
with early stage NSCLC; however, the results of their study 
are not generalizable to patients with higher stage tumors. 
Eventually, they recommend that all patients with resectable 
NSCLC undergo mediastinal LND because the procedure 
does not increase mortality or morbidity.3 As for the other 
controversy, the extent of LND, some surgeons have retro-
spectively analyzed the distribution and prevalence of medi-
astinal lymph node metastasis according to the location of 
the primary tumor (lobe); they suggested the concept of lobe-
specific selective LND based on their analyses.7–12 However, 
it remains unclear whether selective LND can contribute to 
a decrease of the incidence of postoperative complications 
without a negative effect on patient prognosis.8 It is also a fact 
that no large-scale prospective randomized controlled trials 
that compare the clinical implications of systematic LND to 
lobe-specific selective LND have been performed.
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Recent developments of radiological examinations have 
been able to bring more accurate information about the bio-
logical malignancy of primary tumors in NSCLC. Especially 
in cases with small-sized and early NSCLC with ground glass 
opacity (GGO), preoperative thin-section computed tomogra-
phy (TSCT) is an important examination for the evaluation 
and prediction of tumor malignancy. Although there are some 
reports on the association between radiological findings and 
histological grade of the tumor in small-sized NSCLC,13–16 
there are none on the relation between radiological findings of 
the primary tumor on preoperative TSCT and the lobe-specific 
distribution of mediastinal lymph node metastasis.
The aim of this study is to elucidate the optimal candi-
date for lobe-specific selective LND that reduces the extent 
of mediastinal LND according to the clinical information 
including radiological evaluation on TSCT and tumor location 
in clinical stage (c-stage) I NSCLC patients.
MATERIALS AND METHODS
Study Population
Between January 2003 and December 2009, 1923 con-
secutive patients underwent pulmonary resection for lung can-
cer in National Cancer Center Hospital East (Kashiwa, Chiba, 
Japan). Of these, we reviewed 876 patients who were diagnosed 
as having c-stage I NSCLC according to the 7th edition Tumor–
Node–Metastasis classification and underwent complete surgi-
cal resection by lobectomy or greater and systematic LND in this 
study. Complete resection was defined as an absence of residual 
cancer both macroscopically and microscopically (R0). Patients 
who underwent limited resections (segmentectomy or wedge 
resection), incomplete resection were excluded. Histological 
minorities, such as large cell carcinoma, large cell neuroen-
docrine carcinoma, carcinoids, pleomorphic carcinoma, and 
mucoepidermoid carcinoma were excluded, and we performed 
an analysis only for adenocarcinoma and squamous cell carci-
noma cases. We reviewed the medical records of each patient 
for clinicopathological information as follows: age, sex, smok-
ing status (never or ever smoker), preoperative serum carcino-
embryonic antigen (CEA) level (cutoff at the normal upper limit 
of 5.0 ng/ml), tumor laterality (right or left side), tumor loca-
tion (right upper lobe [RUL], right middle lobe [RML], right 
lower lobe [RLL], left upper division [LUD], left lingular divi-
sion [LLD], or left lower lobe [LLL]), radiological findings (as 
described below), clinical T factor (c-T factor; cT1a to cT2a), 
pathological T factor (p-T factor; pT1a to pT4), pathological N 
factor (p-N factor; pN0 to pN3), pathological stage (p-stage; pIA 
to pIV), histology, lymphatic permeation (negative or positive), 
vascular invasion (negative or positive), pleural invasion (nega-
tive or positive), and distribution of each mediastinal lymph node 
metastasis. Data collection and analyses were approved, and the 
need to obtain written informed consent from each patient was 
waived by the Institutional Review Board in June 2012.
Preoperative Staging
All patients with cT1N0M0 lung cancer were clinically 
staged using a 5- to 10-mm-collimated contrast-enhanced CT 
scan (Toshiba, Aquillion 16, TSX301A/GB) of the chest and 
upper abdomen. Primary lesions were also evaluated using 1- 
to 2-mm-collimation TSCT images. Lymph nodes larger than 
1.0 cm in the short axis on chest CT were clinically defined 
as metastasis-positive. Mediastinoscopy or positron emis-
sion tomography (PET) scan was not routinely performed 
preoperatively during the period of this study. Most patients 
except for those with early lung cancer underwent a systemic 
work-up: either contrast-enhanced brain CT or magnetic reso-
nance imaging of the brain, bone scintigraphy, and contrast-
enhanced whole-abdominal CT scan.10 If patients underwent 
PET scan of the whole body, bone scintigraphy and enhanced 
whole-abdominal CT scan were often skipped. All patients 
preoperatively underwent an electrocardiogram and respira-
tory function test for cardiopulmonary work up. Clinical stage 
during the study period was determined according to the 6th 
edition Tumor–Node–Metastasis classification in the period of 
this study. For this study, we restaged all cases according to 
the 7th edition Tumor–Node–Metastasis classification.
Radiological Evaluations of Primary Tumors
We evaluated primary tumors on chest CT within 1 month 
before the operation, and their size was determined based 
on the findings of TSCT scan. GGO was defined as a misty 
increase in lung attenuation that did not obscure the underly-
ing vascular markings. The solid component was defined as 
an area of increased opacification, which completely obscured 
underlying vascular markings.13 For all tumors, we obtained 
the maximum dimension of the tumor (tumor) and solid com-
ponent (consolidation) using a lung window level setting from 
the TSCT scan images, and estimated the consolidation-to-
tumor ratio (C/T ratio) for each tumor. We defined tumors 
with C/T ratios less than or equal to 0.5 as GGO-predominant 
tumors, and tumors with C/T ratios greater than 0.5 as solid-
predominant tumors. Each lung nodule on preoperative TSCT 
scans was reviewed by two thoracic surgeons (T. H. and K.A.), 
who were unaware of the pathological findings and prognosis.
Pathological Evaluation
During the period of this study, pathological evaluations 
of all cases were performed by a single pulmonary pathologist 
(I. G.). All surgical specimens were fixed with 10% formalin 
and embedded in paraffin. Serial 4-μm sections were stained 
using hematoxylin-eosin (HE) stain. The Victoria blue-van 
Gieson (VVG) method was used to visualize elastic fibers, and 
the Alcian blue-periodic acid Schiff method was used to detect 
cytoplasmic mucin production. Blood and lymphatic vessels 
were identified by HE and VVG staining. Vascular invasion 
and lymphatic permeation were histologically diagnosed by 
identifying cancer cells within blood and lymphatic vessels, 
respectively. Pleural invasion was evaluated by VVG staining. 
Pleural invasion was considered to be present when tumor 
cells were identified beyond the elastic layer of the visceral 
pleura, regardless of tumor exposure on the pleural surface. 
We evaluated all dissected hilar and mediastinal lymph nodes 
which harvested in the operation, and each lymph node was 
evaluated on the maximum cut surface. Histologic analy-
sis of lymph node metastasis was carried out by HE stain-
ing. Histological classification of the resected specimens 
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was determined according to the World Health Organization 
International Histologic Classification of Tumors.17 Genetic 
alterations responsible for lung cancer (e.g., EGFR or ALK) 
were not routinely analyzed during the period of this study.
Distribution of Mediastinal Lymph  
Node Metastasis
We categorized and defined mediastinal lymph 
nodes according to the 7th edition Tumor–Node–Metastasis 
Classification.18 The sites of mediastinal lymph nodes were 
grouped based on the IASLC staging19 as follows: upper medi-
astinal lymph nodes (UMLN) included #2R and #4R lymph 
nodes in cases of right lung cancer. UMLN included #4L, #5, 
and #6 lymph nodes in cases of left lung cancer. In both sides, 
subcarinal lymph nodes (SCLN) were the #7 lymph node and 
lower mediastinal lymph nodes (LMLN) included the #8 and #9 
lymph nodes. Skip metastasis was generally defined as medias-
tinal lymph node metastasis without intrapulmonary, interlobar, 
and hilar lymph node metastasis. In this study, “mediastinal skip 
metastasis” was defined as SCLN metastasis without UMLN 
metastasis for right upper-lobe and left upper-division primary 
NSCLC and UMLN metastasis without SCLN metastasis for 
bilateral lower-lobe primary NSCLC on the basis of lymph node 
grouping of General Rule for Clinical and Pathological Record 
of Lung Cancer of the Japan Lung Cancer Society. We analyzed 
the association of mediastinal lymph node metastasis with clini-
cal factors: age, sex, smoking status, preoperative serum CEA 
level, tumor laterality, tumor size, and radiological findings.
Statistical Analysis
Two-category comparison was performed by Pearson’s 
χ2 test and Fisher’s exact test for quantitative data, and contin-
uous data were analyzed by Mann–Whitney U test. A p value 
less than 0.05 was considered to be significant in statistical 
analyses. Data were analyzed using StatView for Windows 
version 5.0 (SAS Inc., Cary, NC).
RESULTS
Clinicopathological Characteristics of Patients
The patients included 490 men and 386 women, with a 
median age of 66 years old (range: 35–89). There were 347 
never smokers and 529 ever smokers. The tumor location was 
RUL in 302 patients, RML in 59 patients, RLL in 187 patients, 
left upper lobe in 188 patients (LUD in 153 patients and LLD 
in 35 patients), and LLL in 140 patients. The radiological find-
ings were GGO predominant in 134 patients and solid pre-
dominant in 742 patients. The median tumor diameter was 
2.5 cm (range: 0.5–5.0). Histologic type was adenocarcinoma 
in 744 patients, squamous cell carcinoma in 132 patients.
Distribution and Incidence of 
Mediastinal Lymph Node Metastasis 
Based on the Tumor Location
Figure 1 shows the distribution and incidence of lymph 
node metastasis in each mediastinal region based on the pri-
mary tumor location.
RUL (n = 302): Twenty-six cases (8.6%) were positive 
for mediastinal lymph node metastasis. All 26 cases were pos-
itive for UMLN metastasis, and four cases (1.3%) were posi-
tive also for SCLN (Fig. 1A).
LUD (n = 153): Nine cases (5.8%) were positive for 
mediastinal lymph node metastasis. Of these, eight cases 
(5.2%) were positive for UMLN metastasis, and one case 
(0.7%) was positive for SCLN (Fig. 1B).
RML (n = 59): Five cases (8.5%) were positive for medi-
astinal lymph node metastasis. Of these, four cases (6.8%) 
were positive for UMLN metastasis, two cases (3.4%) were 
positive for SCLN, and one case (1.7%) was positive for 
LMLN (Fig. 1C).
LLD (n = 35): Four cases (11.4%) were positive for medi-
astinal lymph node metastasis, including a pN3 case that had 
beaded metastasis of subcarinal and contralateral hilar lymph 
nodes. Of these, three cases (8.6%) were positive for UMLN 
metastasis, and one case (2.9%) was positive for SCLN (Fig. 1D).
RLL (n = 187): Thirteen cases (7.0%) were positive 
for mediastinal lymph node metastasis. Of these, five cases 
(2.7%) were positive for UMLN metastasis, 10 cases (5.3%) 
were positive for SCLN, and six cases (3.2%) were positive 
for LMLN (Fig. 1E).
LLL (n = 140): Twenty-three cases (16.4%) were posi-
tive for mediastinal lymph node metastasis. Of these, 11 cases 
(7.8%) were positive for UMLN metastasis, 14 cases (10.0%) 
were positive for SCLN, and four cases (2.9%) were positive 
for LMLN (Fig. 1F).
Incidence of Mediastinal Lymph Node 
Metastasis According to Histological Types
There were 744 adenocarcinoma cases and 132 squa-
mous cell carcinoma cases in this study. The incidences of 
mediastinal lymph node metastasis were 9.9% (74 of 744) in 
adenocarcinoma cases and 4.5% (6 of 132) in squamous cell 
carcinoma cases, respectively.
With regard to six squamous cell carcinoma cases with 
mediastinal lymph node metastasis, there were five men and a 
woman. All patients were ever smokers, and had a radiologi-
cally solid-predominant tumor. The primary tumor location 
was RUL in two patients, RLL in one patient, and LLL in 
three patients. Among them, two upper-lobe cases were posi-
tive for UMLN metastasis, and three lower-lobe cases were 
positive for SCLN or LMLN metastasis, and only one LLL 
case was positive for UMLN metastasis.
Associated Clinical Factors of 
Mediastinal Lymph Node Metastasis 
in Adenocarcinoma Cases
Table 1 shows the associated clinical factors for medi-
astinal lymph node metastasis in adenocarcinoma cases. Age 
(p = 0.019), elevated serum CEA level (≥5.0; p < 0.001), and 
radiological solid-predominant tumors (p < 0.001) showed 
significant associations with mediastinal lymph node metas-
tasis. Remarkably, there were no mediastinal lymph node 
metastases in GGO-predominant tumors. Larger tumor size 
(>2.0 cm, ≤5.0 cm) was not associated with mediastinal lymph 
node metastasis (p = 0.158).
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Distributions and Incidences of Mediastinal 
Skip Metastasis in Adenocarcinoma Cases
Table 2 shows a detailed analysis of the distributions 
and incidences of mediastinal skip metastasis. In 398 RUL 
and LUD primary lung adenocarcinoma, a total of 33 cases 
(8.3%) were positive for mediastinal lymph node metastasis, 
and only one case (0.3%) was negative for UMLN metasta-
sis but positive for SCLN metastasis. On the other hand, in 
257 RLL and LLL primary lung adenocarcinoma, a total of 
32 cases (12.5%) were positive for mediastinal lymph node 
metastasis, and seven cases (2.7%) were negative for SCLN 
metastasis but positive for UMLN metastasis.
Associated Clinical Factors of UMLN 
Metastasis in Bilateral Lower-Lobe 
Primary Lung Adenocarcinoma with 
Radiologically Solid-Predominant Tumor
Table 3 shows the association of UMLN metastasis with 
clinical factors including histological type in bilateral lower-lobe 
primary adenocarcinoma with radiologically solid-predominant 
tumor. Among these factors, elevated serum CEA level (≥5.0; 
p < 0.001) showed significant associations with UMLN metastasis.
DISCUSSION
Lobectomy with systematic LND is a globally accepted 
procedure for resectable primary NSCLC as a standard 
operation.1 Although there is a global consensus on the defini-
tion of systematic LND that indicates the extent of mediasti-
nal lymph node to dissect and remove, there are some different 
interpretations of systematic LND among institutions and 
countries. The European Society of Thoracic Surgeons rec-
ommends the dissection of at least three mediastinal nodal 
regions (but always subcarinal) as a minimum requirement of 
systematic LND.20,21 In Japan, mediastinal lymph nodes were 
divided into three groups (group 2a-1, group 2a-2, and group 
2b) according to the primary tumor location, and the extent 
of LND was determined on the basis of these groups (ND2a-
1, ND2a-2, and ND2b) in the General Rules for Clinical and 
Pathological Records of Lung Cancer of the Japan Lung 
Cancer Society 2010.22 LND is performed based on these 
rules for almost all cases. Lobe-specific selective LND is 
conventionally described as ND2a-1 in Japan, which means 
that the mediastinal tissue containing specific lymph node sta-
tions is excised depending on the lobar location of the primary 
tumor. However, some retrospective studies have revealed the 
distributions of mediastinal lymph node metastasis in relation 
to primary tumor location and the significance of lobe-specific 
selective LND,7–12,23–25 but its validity or the prognostic effect 
of lobe-specific selective LND has not been confirmed in a 
large-scale prospective study.
We analyzed the radiological findings of primary tumor 
on preoperative TSCT and evaluated the association between 
C/T ratio and mediastinal lymph node metastasis in this study. 
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FIGURE 1.  Distribution and incidence of lymph node metastasis in each mediastinal region based on the tumor location. A, 
Right upper lobe. B, Left upper division. C, Right middle lobe. D, Left lingular division. E, Right lower lobe. F, Left lower lobe. 
UMLN, upper mediastinal lymph nodes; SCLN, subcarinal lymph nodes; LMLN, lower mediastinal lymph nodes.
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In previous reports, the incidence of mediastinal lymph node 
metastasis was extremely low in c-stage I NSCLC cases with 
GGO-predominant tumor.13,16,26 In recent years, the opportu-
nity to detect lung nodules with a GGO component has been 
increasing owing to the wide spread of CT screening and the 
resolution-enhancement technology of TSCT.27–29 Several 
authors have reported that it was useful to evaluate the detailed 
radiological features to predict tumor invasiveness.14,16 A pro-
spective radiological study in Japan (JCOG0201) has been 
conducted to demonstrate the predictive TSCT criterion of 
pathological noninvasiveness for c-stage I NSCLC.15 In addi-
tion, there are a few reports that describe detailed analyses 
based on radiological findings on TSCT for the distribution 
and prevalence of mediastinal lymph node metastasis in 
c-stage I NSCLC.
Our results suggest that selective LND might be accept-
able for GGO-predominant cases in the sense that there would 
probably be no remaining metastatic lymph nodes by selective 
LND. Moreover, it might be unnecessary to perform hilar and 
mediastinal LND itself for GGO-predominant lung cancer. On 
the other hand, there were a lot of cases with unexpected hilar 
and mediastinal lymph node metastasis in solid-predominant 
tumors. All primary tumors with hilar and mediastinal lymph 
TABLE 1.  Association of Clinicopathological Factors with 
Mediastinal Lymph Node Metastasis in C-Stage I Lung 
Adenocarcinoma
Total
Mediastinal Lymph 
Node Metastasis
Positive
N = 744 N = 74 (%) p Value
Age (years old)
  Median 66 (range: 35–89) 0.019a
Sex
  Men 371 41 (11.1) 0.329
  Women 373 33 (8.8)
Smoking status
  Never smoker 345 30 (8.7) 0.326
  Ever smoker 399 44 (11.0)
Preoperative serum CEA level (ng/ml)
  <5.0 558 41 (7.3) <0.001
  ≥5.0 186 33 (17.7)
Tumor laterality
  Right 478 41 (8.6) 0.098
  Left 266 33 (12.4)
Tumor size (cm)
  ≤2.0 260 20 (7.7) 0.158
  >2.0, ≤5.0 484 54 (11.2)
Radiographic findings
  GGO-predominant 133 0 (0) <0.001
  Solid-predominant 611 74 (10.0)
aMann–Whitney U test.
CEA, carcinoembryonic antigen; GGO, ground glass opacity.
TABLE 2.  Distributions and Incidences of Lymph Node 
Metastasis in Each Mediastinal Region Based on the Primary 
Tumor Location in C-Stage I Lung Adenocarcinoma 
RUL and LUD primary tumor N = 398
UMLN Metastasis
Positive
N (%)
Negative
N (%)
SCLN metastasis Positive
N (%)
4 (1.0) 1 (0.3)
Negative
N (%)
28 (7.0) 365 (91.7)
RLL and LLL primary tumor N = 257
UMLN Metastasis
Positive
N (%)
Negative
N (%)
SCLN metastasis Positive
N (%)
8 (3.1) 14 (5.4)
Negative
N (%)
7 (2.7) 225 (87.5)
RUL, right upper lobe; LUD, left upper division; RLL, right lower lobe; LLL, left 
lower lobe; UMLN, upper mediastinal lymph nodes; SCLN, subcarinal lymph nodes.
TABLE 3.  Association of Clinicopathological Factors with 
Upper Mediastinal Lymph Node Metastasis in Bilateral Lower-
Lobe Primary Lung Adenocarcinoma with Radiologically 
Solid-Predominant Tumor
Total
Upper Mediastinal Lymph 
Node Metastasis
Positive
N = 200 N = 15 (%) p Value
Age (years old)
  Median 67 (range: 37–89) 0.055a
Sex
  Men 98 7 (7.1) >0.999
  Women 102 8 (7.8)
Smoking status
  Never smoker 95 9 (9.5) 0.422
  Ever smoker 105 6 (5.7)
Preoperative serum  
CEA level (ng/ml)
  <5.0 144 4 (2.8) <0.001
  ≥5.0 56 11 (19.6)
Tumor laterality
  Right 114 5 (4.4) 0.062
  Left 86 10 (11.6)
Tumor size (cm)
  ≤2.0 53 2 (3.8) 0.362
  >2.0, ≤5.0 147 13 (8.8)
Tumor location
  Upper segment 68 8 (11.8) 0.154
  Basal segment 132 7 (5.3)
aMann–Whitney U test.
CEA, carcinoembryonic antigen.
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node metastasis were solid predominant, so we cannot help 
but be careful to apply a reduction in the extent of LND to 
these populations. From the perspective of lobe-specific selec-
tive LND, the incidence of SCLN metastasis was only 1.3% 
(5 of 398 cases), and only one case (0.3%) was positive for 
SCLN metastasis but negative for UMLN metastasis in pri-
mary adenocarcinoma located in the RUL and LUD. There 
were no predictive clinical factors of SCLN metastasis in RUL 
and LUD primary adenocarcinoma; however, there would be 
some possibility to omit SCLN dissection because the inci-
dence of SCLN metastasis was extremely low, even in solid-
predominant c-stage I NSCLC cases. On the other hand, the 
incidence of UMLN metastasis in lower-lobe primary NSCLC 
was much higher than that of SCLN metastasis in upper-lobe 
primary NSCLC because of its lymphatic drainage pathway. 
With regard to the selective LND of lower-lobe NSCLC, there 
are some reports that demonstrate the usefulness of intraoper-
ative frozen section diagnosis of mediastinal lymph nodes9,30; 
namely, UMLN dissection might be unnecessary for lower-lobe 
tumors when the SCLN is intraoperatively negative. However, 
half of lower-lobe cases with UMLN metastasis had no metas-
tasis of SCLN in our study. A lot of care must be taken for the 
application of selective LND for solid- predominant tumors 
located in bilateral lower lobes. According to the analysis in 
our study, CEA elevation was a significant associated factor 
of UMLN metastasis in lower-lobe primary lung adenocar-
cinoma with radiologically solid-predominant tumor. Hattori 
et al.26 revealed that CEA elevation was a significant predic-
tor of lymph node involvement in c-stage I NSCLC cases, 
and they suggested that incomplete dissection or sampling 
of lymph nodes for solid-predominant tumor could result in 
locoregional recurrence. Considering the results of our study, 
it might be possible to omit UMLN dissection for lower-lobe 
primary tumors with a normal level of CEA; however, it is 
necessary to investigate more cases with long term follow-up 
to confirm the possibility.
We should also pay careful attention to the possibility of 
skip mediastinal lymph node metastasis. There were one right 
upper-lobe case with SCLN skip metastasis and seven lower-
lobe cases with UMLN skip metastasis in our study. It is well 
known that there are pulmonary lymphatic pathways directly 
to the mediastinum. Gorai et al.31 suggested that the incidence 
of skip N2 was significantly associated with pleural involve-
ment in patients with clinical IA NSCLC and in those with 
nodal metastasis, and assumed an involvement of the subpleu-
ral lymphatic drainage. In addition, Takahashi et al.32,33 dem-
onstrated a predictable pattern of lobar lymphatic drainage to 
the mediastinum by the assessment of CT studies of patients 
with primary complex histoplasmosis consisting of a single 
lobe pulmonary lesion and mediastinal nodal disease. They 
revealed that there were seven of 122 (5.7%) upper-lobe cases 
with skip SCLN involvement and 14 of 129 (10.8%) lower-
lobe cases with skip UMLN involvement in their study. The 
data from their study would lead to our good understanding 
of lymphatic drainage pathways of each lobe and segment to 
the mediastinum.
Limitations of this study include the potential intro-
duction of surgical and selection bias associated with the 
retrospective assessment of data. Another limitation of this 
study is that the presented data are derived from a single 
institution, and there were not a sufficient number of cases, 
especially nonadenocarcinoma cases, to reach a definitive 
conclusion. In addition, the calculation of C/T ratio was per-
formed only by thoracic surgeons, not including thoracic radi-
ologist. There was no internal observer who decided whether 
there were any interreader variabilities. Finally, preopera-
tive mediastinal evaluations by PET/CT or endobronchial 
ultrasonography-transbronchial needle aspiration were not 
routinely performed during the period of this study because 
of the inclusion of almost data from old cases, collected at 
a time when these examinations were less established. It is 
imperative to perform a large-scale prospective randomized 
trial that compares systematic LND to selective LND for 
solid-predominant NSCLC.
In conclusion, we demonstrated the association of 
clinical factors including radiological findings on TSCT with 
mediastinal lymph node metastasis. It would be acceptable 
to perform selective LND for c-stage I GGO-predominant 
tumors; moreover, it might be possible to omit mediastinal 
LND itself for those cases. On the other hand, we should be 
careful to apply selective LND to c-stage I solid-predominant 
tumors, especially those located in the lower lobe. CEA eleva-
tion was significantly associated with UMLN metastasis in 
lower-lobe primary c-stage I lung adenocarcinoma with radio-
logically solid-predominant tumors. It would be necessary to 
perform well-designed prospective clinical trials to evaluate 
the indication of selective LND.
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